Proteomics for biomarker discovery in malignant melanoma

References

• Markovic S, Erickson L, Rao R et al. Malignant melanoma in the 21st Century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin. Proc.82(3), 364–380 (2007).
   PubMed Web of Science ®Google Scholar
• Brochez L, Naeyaert J. Serological markers for melanoma. Br. J. Dermatol.143(2), 256–268 (2000).
   PubMedGoogle Scholar
• Linette G, Carlson J, Slominski A, Mihm M, Ross J. Biomarkers in melanoma: stage III and IV disease. Expert Rev. Mol. Diagn.5(1), 65–74 (2005).
   PubMed Web of Science ®Google Scholar
• Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr. Opin. Oncol.17(2), 167–171 (2005).
   PubMed Web of Science ®Google Scholar
• Utikal J, Schadendorf D, Ugurel S. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch. Dermatol. Res.298(10), 469–477 (2007).
   PubMedGoogle Scholar
• Bosserhoff A. Novel biomarkers in malignant melanoma. Clin. Chim. Acta367(1–2), 28–35 (2006).
   PubMed Web of Science ®Google Scholar
• Rifai N, Gillette M, Carr S. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol.24(8), 971–983 (2006).
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin REF, Liotta L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv. Exp. Med. Biol.532, 59–68 (2003).
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature422(6928), 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Hortin G. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem.52(7), 1223–1237 (2006).
   PubMed Web of Science ®Google Scholar
• Ahn N, Shabb J, Old W, Resing K. Achieving in-depth proteomics profiling by mass spectrometry. ACS Chem. Biol.2(1), 39–52 (2007).
   PubMed Web of Science ®Google Scholar
• Tannu N, Hemby S. Two-dimensional fluorescence difference gel electrophoresis for comparative proteomics profiling. Nat. Protoc.1(4), 1732–1742 (2006).
   PubMed Web of Science ®Google Scholar
• Maurya P, Meleady P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res.27(3A), 1247–1255 (2007).
   PubMed Web of Science ®Google Scholar
• Clauser K, Hall S, Smith D et al. Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc. Natl Acad. Sci. USA92(11), 5072–5076 (1995).
   PubMed Web of Science ®Google Scholar
• de Souza G, Godoy L, Teixeira V et al. Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics6(5), 1460–1470 (2006).
   PubMed Web of Science ®Google Scholar
• Buscà R, Berra E, Gaggioli C et al. Hypoxia-inducible factor 1a is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J. Cell Biol.170(1), 49–59 (2005)
   PubMed Web of Science ®Google Scholar
• Sinha P, Kohl S, Fischer J et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis21(14), 3048–3057 (2000).
   PubMed Web of Science ®Google Scholar
• Poland J, Schadendorf D, Lage H et al. Study of therapy resistance in cancer cells with functional proteome analysis. Clin. Chem. Lab. Med.40(3), 221–234 (2002).
   PubMed Web of Science ®Google Scholar
• Sinha P, Poland J, Kohl S et al. Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis24(14), 2386–2404 (2003).
   PubMed Web of Science ®Google Scholar
• Carta F, Demuro P, Zanini C et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res.15(4), 235–244 (2005).
   PubMedGoogle Scholar
• Anderson N, Polanski M, Pieper R et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics3(4), 311–326 (2004).
   PubMed Web of Science ®Google Scholar
• Bernard K, Litman E, Fitzpatrick J et al. Functional proteomic analysis of melanoma progression. Cancer Res.63(20), 6716–6725 (2003).
   PubMed Web of Science ®Google Scholar
• Pardo M, Garcia A, Thomas B et al. Proteome analysis of a human uveal melanoma primary cell culture by 2-DE and MS. Proteomics5(18), 4980–4993 (2005).
   PubMedGoogle Scholar
• Zuidervaart W, Hensbergen P, Wong M-C et al. Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest. Ophthalmol. Vis. Sci.47(3), 786–793 (2006).
   PubMed Web of Science ®Google Scholar
• Pardo M, Dwek R, Zitzmann N. Proteomics in uveal melanoma research: opportunities and challenges in biomarker discovery. Expert Rev. Proteomics4(2), 273–286 (2007).
   PubMed Web of Science ®Google Scholar
• Pardo M, Garcia A, Thomas B et al. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int. J. Cancer119(5), 1014–1022 (2006).
   PubMed Web of Science ®Google Scholar
• Culp W, Neal R, Massey R et al. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J. Proteome Res.5(6), 1332–1343 (2006).
   PubMedGoogle Scholar
• Issaq H, Veenstra T. The role of electrophoresis in disease biomarker discovery. Electrophoresis28(12), 1980–1988 (2007).
   PubMedGoogle Scholar
• Hoffman S, Won AJ, Echan L, Speicher D. Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.849(1–2), 43–52 (2007).
   PubMed Web of Science ®Google Scholar
• Deutsch E, Eng J, Zhang H et al. Human Plasma PeptideAtlas. Proteomics5(13), 3497–3500 (2005).
   PubMed Web of Science ®Google Scholar
• States D, Omenn G, Blackwell T et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol.24(3), 333–338 (2006).
   PubMed Web of Science ®Google Scholar
• Lee H-J, Lee E-Y, Kwon M-S, Paik Y-K. Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics. Curr. Opin. Chem. Biol.10(1), 42–49 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bast JRC, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res.64(16), 5882–5890 (2004).
   PubMed Web of Science ®Google Scholar
• Pusch W, Flocco M, Leung S-M, Thiele H, Kostrzewa M. Mass spectrometry-based clinical proteomics. Pharmacogenomics4(4), 463–476 (2003).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Philip J, Entenberg D et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem.76(6), 1560–1570 (2004).
   PubMed Web of Science ®Google Scholar
• Lopez M, Mikulskis A, Kuzdzal S et al. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem.53(6), 1067–1074 (2007).
   PubMed Web of Science ®Google Scholar
• Tomecki K, Montague P, Hearing JV. Serum and urine protein differences in patients with malignant melanoma. J. Natl Cancer Inst.64(1), 29–32 (1980).
   PubMedGoogle Scholar
• Ferrari L, Seraglia R, Rossi C et al. Protein profiles in sera of patients with malignant cutaneous melanoma. Rapid Commun. Mass Spectrom.14(13), 1149–1154 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson L, Tran L, Morton D, Hoon D. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann. NY Acad. Sci.1022, 317–322 (2004).
   PubMed Web of Science ®Google Scholar
• Mian S, Ugurel S, Parkinson E et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol.23(22), 5088–5093 (2005).
   PubMed Web of Science ®Google Scholar
• Matharoo-Ball B, Ratcliffe L, Lancashire L et al. Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach. Proteomics Clin. Applic.1(6), 605–620 (2007).
   PubMedGoogle Scholar
• Ragazzi E, Vogliardi S, Allegri G et al. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers. Rapid Commun. Mass Spectrom.17(13), 1511–1515 (2003).
   PubMedGoogle Scholar
• Seraglia R, Vogliardi S, Allegri G et al. Search for melanoma markers in plasma and serum samples. Eur. J. Mass Spectrom.11(3), 353–360 (2005).
   PubMedGoogle Scholar
• Mischak H, Apweiler R, Banks R et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin. Applic.1(2), 148–156 (2007).
   PubMed Web of Science ®Google Scholar
• Deichmann M, Kahle B, Moser K, Wacker J, Wüst K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br. J. Cancer91(4), 699–702 (2004).
   PubMed Web of Science ®Google Scholar
• Koomen J, Zhao H, Li D et al. Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. Rapid Commun. Mass Spectrom.19(12), 1624–1636 (2005).
   PubMedGoogle Scholar
• Missotten G, Beijnen J, Keunen J, Bonfrer J. Proteomics in uveal melanoma. Melanoma Res.13(6), 627–629 (2003).
   PubMed Web of Science ®Google Scholar
• Kaiser T, Wittke S, Just I et al. Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis25(13), 2044–2055 (2004).
   PubMed Web of Science ®Google Scholar
• Brouard M, Saurat JH, Ghanem G, Siegenthaler G. Urinary excretion of epidermal-type fatty acid-binding protein and S100A7 protein in patients with cutaneous melanoma. Melanoma Res.12(6), 627–631 (2002).
   PubMedGoogle Scholar
• Kolch W, Neusüss C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev.24(6), 959–977 (2005).
   PubMed Web of Science ®Google Scholar
• Weissinger E, Wittke S, Kaiser T et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int.65(6), 2426–2434 (2004).
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Fliser D, Wittke S et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis26(14), 2797–2808 (2005).
   PubMed Web of Science ®Google Scholar
• Decramer S, Wittke S, Mischak H et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med.12(4), 398–400 (2006).
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Wittke S, Ross M et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol.7(3), 230–240 (2006).
   PubMed Web of Science ®Google Scholar
• Schiffer E, Mischak H, Novak J. High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. Proteomics6(20), 5615–5627 (2006).
   PubMed Web of Science ®Google Scholar
• Diamandis E. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem.49(8), 1272–1275 (2003).
   PubMed Web of Science ®Google Scholar
• Garber K. Debate rages over proteomic patterns. J. Natl Cancer Inst.96(11), 816–818 (2004).
   PubMedGoogle Scholar
• Diamandis E. Serum proteomic profiling by matrix-assisted laser desorption–ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res.66(11), 5540–5541 (2006).
   PubMed Web of Science ®Google Scholar
• Petricoin E, Ardekani A, Hitt B et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet359(9306), 572–577 (2002).
   PubMed Web of Science ®Google Scholar
• Baggerly K, Morris J, Coombes K. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics20(5), 777–785 (2004).
   PubMed Web of Science ®Google Scholar
• Check E, Proteomics and cancer: running before we can walk? Nature429(6991), 496–497 (2004).
   PubMed Web of Science ®Google Scholar
• Semmes O, Cazares L, Ward M et al. Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia19(7), 1229–1238 (2005).
   PubMedGoogle Scholar
• McLerran D, Grizzle WE, Feng Z et al. analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin. Chem.54(1), 44–52 (2008).
   PubMed Web of Science ®Google Scholar
• McLerran D, Grizzle WE, Feng Z et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin. Chem.54(1), 53–60 (2008).
   PubMed Web of Science ®Google Scholar
• Banks R, Stanley A, Cairns D et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem.51(9), 1637–1649 (2005).
   PubMed Web of Science ®Google Scholar
• Findeisen P, Sismanidis D, Riedl M, Costina V, Neumaier A. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem.51(12), 2409–2411 (2005).
   PubMed Web of Science ®Google Scholar
• Baumann S, Ceglarek U, Fiedler G et al. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem.51(6), 973–980 (2005).
   PubMed Web of Science ®Google Scholar
• West-Nielsen M, Hogdall E, Marchiori E et al. Sample handling for mass spectrometric proteomic investigations of human sera. Anal. Chem.77(16), 5114–5123 (2005).
   PubMed Web of Science ®Google Scholar
• West-Norager M, Kelstrup C, Schou C et al. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J. Chromatogr. B847(1), 30–37 (2007).
   PubMed Web of Science ®Google Scholar
• Karsan A, Eigl B, Flibotte S et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem.51(8), 1525–1528 (2005).
   PubMed Web of Science ®Google Scholar
• Ransohoff D. Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl Cancer Inst.97(4), 315–319 (2005).
   PubMed Web of Science ®Google Scholar
• Hong H, Dragan Y, Epstein J et al. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics6(Suppl. 2), 5 (2005).
   PubMedGoogle Scholar
• Villanueva J, Philip J, Chaparro C et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res.4(4), 1060–1072 (2005).
   PubMed Web of Science ®Google Scholar
• Hu J, Coombes K, Morris J, Baggerly K. The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief. Funct. Genomic. Proteomic.3(4), 322–331 (2005).
   PubMedGoogle Scholar
• Taylor C, Paton N, Lilley K et al. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol.25(8), 887–893 (2007).
   PubMed Web of Science ®Google Scholar
• Brazma A, Krestyaninova M, Sarkans U. Standards for systems biology. Nat. Rev. Genet.7(8), 593–605 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson N, Anderson N. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics1(11), 845–867 (2002).
   PubMed Web of Science ®Google Scholar
• Koomen J, Li D, Xiao L-C et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res.4(3), 972–981 (2005).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest.116(1), 271–284 (2006).
   PubMed Web of Science ®Google Scholar
• Omenn G. Strategies for plasma proteomic profiling of cancers. Proteomics6(20), 5662–5673 (2006).
   PubMed Web of Science ®Google Scholar
• Whiteaker J, Zhang H, Eng J et al. Head-to-head comparison of serum fractionation techniques. J. Proteome Res.6(2), 828–836 (2007).
   PubMed Web of Science ®Google Scholar
• Diamandis E. Oncopeptidomics: a useful approach for cancer diagnosis? Clin. Chem.53(6), 1004–1006 (2007).
   PubMed Web of Science ®Google Scholar
• Bossuyt P, Reitsma J, Bruns D et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin. Chem.49(1), 7–18 (2003).
   PubMed Web of Science ®Google Scholar
• Diamandis E. Peptidomics for cancer diagnosis: present and future. J. Proteome Res.5(9), 2079–2082 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez-Otin C, Overall C. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol.3(7), 509–519 (2002).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Martorella A, Lawlor K et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics5(10), 1840–1852 (2006).
   PubMed Web of Science ®Google Scholar
• Capon F, Emonard H, Hornebeck W, Maquart F, Bernard P. Expression and activation of pro-gelatinase A by human melanoma cell lines with different tumorigenic potential. Clin. Exp. Metastasis17(6), 463–469 (1999).
   PubMedGoogle Scholar
• Ntayi C, Labrousse A-L, Debret R et al. Elastin-derived peptides upregulate matrix metalloproteinase-2-mediated melanoma cell invasion through elastin-binding protein. J. Invest. Dermatol.122(2), 256–265 (2004).
   PubMed Web of Science ®Google Scholar
• Jessani N, Niessen S, Wei B et al. A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods2(9), 691–697 (2005).
   PubMedGoogle Scholar
• Conrads T, Hood B, Veenstra T. Sampling and analytical strategies for biomarker discovery using mass spectrometry. Biotechniques40(6), 799–805 (2006).
   PubMed Web of Science ®Google Scholar
• Findeisen P, Post S, Wenz F, Neumaier M. Addition of exogenous reporter peptides to serum samples before mass spectrometry-based protease profiling provides advantages over profiling of endogenous peptides. Clin. Chem.53(10), 1864–1866 (2007).
   PubMedGoogle Scholar
• Villanueva J, Nazarian A, Lawlor K et al. A sequence-specific exopeptidase activity test (SSEAT) for ‘functional’ biomarker discovery. Mol. Cell. Proteomics7(3), 509–518 (2008).
   PubMed Web of Science ®Google Scholar
• Nedelkov D, Kiernan U, Niederkofler E, Tubbs K, Nelson R. Investigating diversity in human plasma proteins. Proc. Natl Acad. Sci. USA102(31), 10852–10857 (2005).
   PubMed Web of Science ®Google Scholar
• Jin M, Cataland S, Bissell M, Wu HM. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J. Thromb. Haemost.4(2), 333–338 (2006).
   PubMedGoogle Scholar
• Mueller L, Rinner O, Schmidt A et al. SuperHirn – a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics7(19), 3470–3480 (2007).
   PubMedGoogle Scholar
• Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics6(12), 2212–2229 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson L, Hunter C. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics5(4), 573–588 (2006).
   PubMed Web of Science ®Google Scholar
• Bondar OP, Barnidge DR, Klee EW, Davis BJ, Klee GG. LC-MS/MS quantification of Zn-α2 glycoprotein: a potential serum biomarker for prostate cancer. Clin. Chem.53(4), 673–678 (2007).
   PubMed Web of Science ®Google Scholar
• Hortin GL. A new era in protein quantification in clinical laboratories: application of liquid chromatography-tandem mass spectrometry. Clin. Chem.53(4), 543–544 (2007).
   PubMedGoogle Scholar
• Veenstra T. Global and targeted quantitative proteomics for biomarker discovery. J. Chromatogr. B847(1), 3–11 (2007).
   PubMed Web of Science ®Google Scholar
• Stahl-Zeng J, Lange V, Ossola R et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics6(10), 1809–1817 (2007).
   PubMed Web of Science ®Google Scholar
• Ackermann B, Berna M. Coupling immunoaffinity techniques with MS for quantitative analysis of low-abundance protein biomarkers. Expert Rev. Proteomics4(2), 175–186 (2007).
   PubMed Web of Science ®Google Scholar
• Ueda K, Katagiri T, Shimada T et al. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J. Proteome Res.6(9), 3475–3483 (2007).
   PubMedGoogle Scholar
• Caron M, Choquet-Kastylevsky GV, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol. Cell. Proteomics6(7), 1115–1122 (2007).
   PubMed Web of Science ®Google Scholar
• Usener D, Gerhardt A, Schadendorf D, Eichmüller S. Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients. Br. J. Dermatol.149(2), 282–288 (2003).
   PubMedGoogle Scholar
• Hartmann T, Bazhin A, Schadendorf D, Eichmüller S. SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int. J. Cancer114(1), 88–93 (2005).
   PubMed Web of Science ®Google Scholar
• Ladewig G, Reinhold U, Thirkill C et al. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br. J. Dermatol.152(5), 931–938 (2005).
   PubMedGoogle Scholar
• Hardouin J, Lasserre J-P, Sylvius LK, Joubert-Caron R, Caron M. Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann. NY Acad. Sci.1107, 223–230 (2007).
   PubMed Web of Science ®Google Scholar